This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Kadmon Holdings, Inc.
Drug Names(s): AAV2hAQP1
Description: Kadmon is developing an Adeno-associated virus vector containing the human aquaporin-1 gene (AAV2hAQP1).
Kadmon and National Institute of Dental and Craniofacial Research
In June 2014, Kadmon and the National Institute of Dental and Craniofacial Research (NIDCR), an institute of the National Institutes of Health, established a Cooperative Research and Development Agreement (CRADA) to develop an Adeno-associated virus vector containing the human aquaporin-1 gene (AAV2hAQP1) for the treatment of xerostomia resulting from the use of ionizing radiation (IR) in the treatment of head and neck cancer.
Under terms of the agreement, Kadmon and NIDCR will conduct a Phase I study to test the safety of single escalating doses of AAV2hAQP1. Effectiveness, measured by increase in parotid gland salivary output post-IR, will also be tested for up to three years.
Partners: National Institute of Dental and Craniofacial Research
Pink Sheet FDA Performance Tracker: User Fee Goal Dates
Additional information available to subscribers only: